pocketful Page

Home

Calculator

Calculators

search

Search

whatsapp

Whatsapp

Twenty First Century Management Services Ltd

Sequent Scientific Ltd

BSE : 512529|NSE : SEQUENT|ISIN : INE807F01027

Sequent Scientific Ltd Company History

Sequent Scientific is a leading integrated pharmaceutical company with a global footprint, operating in the domains of Active Pharmaceutical Ingredients.

2003
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2020
2021

2003

Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd.

2003

history-arrow-left

2007

PI Drugs & Pharmaceuticals Ltd has informed that Dr. Gopakumar G Nair has joined the Board as Independent Director effective June 20, 2007.

2007

history-arrow-left

2008

PI Drugs Board recommends dividend @ 10%

2008

history-arrow-left

2009

PI Drugs & Pharmaceuticals Ltd equity shareholders approve Scheme of Amalgamation

PI Drugs & Pharmaceuticals Ltd Board recommends Dividend@ 10%

PI Drugs & Pharmaceuticals Ltd - Change of name of the Company from PI Drugs & Pharmaceuticals Ltd to Sequent Scientific Ltd.

2009

history-arrow-left

2010

SeQuent Scientific to invest Rs. 150 crore in three new therapeutic segments - Signs an MoU with Karnataka Government.

2010

history-arrow-left

2011

PI Drugs & Pharmaceuticals Ltd Appoined Mr. Vinayak Hegde as Company Secretary .

2011

history-arrow-left

2012

PI Drugs - Issue of Warrants on Preferential basis

PI Drugs - Alloted 10,00,000 fully paid equity shares of Rs. 10/- each

Registered Office of the Company has been shifted from No. 116, Vardhaman Industrial Complex, Lal Bahaddur Shastri Marg, Thane west - 400 601 to 301, 'Dosti Pinnacle', 3rd Floor, Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W) - 400 604.

2012

history-arrow-left

2013

Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore.

Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company.

2013

history-arrow-left

2014

SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group.

Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business.

Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey.

2014

history-arrow-left

2015

SeQuent Scientific to acquire Animal Health business of Lyka Exports

SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru

2015

history-arrow-left

2016

SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone

Sequent Scientific commences production in Vizag facility

2016

history-arrow-left

2017

SeQuent Scientific said that , its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh.

2017

history-arrow-left

2018

SeQuent Scientific Limited (SeQuent), has said that its wholly owned subsidiary Alivira Animal Health Limited (“Alivira”) through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100 per cent of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany .

2018

history-arrow-left

2020

Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai

SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru

2020

history-arrow-left

2021

Sequent Scientific forays into pet segment in Brazil

The company has said that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Saúde e Nutrição Animal Ltda ('Nourrie').

In this regard,

SeQuent Scientific Limited (SeQuent) has said that European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey.

SeQuent received CEP approval for Diclazuril API

2021

history-arrow-left
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548):

The SEBI Registration No. allotted to us is INZ000313732.
NSE Member Code: 90326| BSE Member Code: 6808| MCX Member Code: 57120
DP CDSL: 12099800

Compliance Officer : Mr. Randhir Kumar Chaudhari
Tel no: 011- 49022222 / 011-49022277
Email: randhir@pocketful.in

Address/Correspondence Address: C- 3, Ground Floor, Okhla Industrial Area, Phase - 1, New Delhi - 110020

For any complaints, drop us an email at legal@pocketful.in

Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID.

Smart Online Dispute Resolution|Link To Circular|Procedures and Policies|Broker Investor Charter|DP Investor Charter

Benefits: Effective Communication, Speedy redressal of the grievances.

Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI and our Terms of Use and Privacy Policy.
The brand name Pocketful and logo is in process of trademarks registration. The cost-effective brokerage plans make Pocketful a trustworthy and reliable online stock broker. Available on both the web and mobile, it offers unmatched convenience to traders. If you are considering opening......

Read More